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Abstract
Background: Eosinophilic esophagitis (EoE) is a complex pathology. Attempts have been made in order to relate EoE
with the intake of certain food. The problem is to establish which foods are really involved in the pathophysiology of this
condition and to objectify a reliable inflammation biomarker for the follow-up of patients undergoing pharmacological
treatment and/or diets. Our aim is to assess the food sensitization profile of patients with objective diagnosis of EoE and
objectify the utility of ECP as an inflammation biomarker for the follow-up of patients with EoE treated with specific diets,
based on the hypothesis that we will observe a decrease and clinical improvement after maintenance of these diets.
Methods: A total of 19 subjects were included between 1 January 2012 and 30 June 2015. Diets based on allergy testing
were established. Prior to the initiation of the diets, baseline ECP was determined. Appointments were arranged for the
patients between 4 and 6 months later to assess the clinical response to the specific diets and to request a second blood
sample for blood counts and serum ECP levels to compare with the previous baseline.
Results: 19 patients diagnosed with EoE (12 males and 7 females) between January 2012 and June 2015, aged
between 17 and 68 (33.52; SD 13.67 years), were included consecutively, 15 of whom showed optimum response to
specific diets based on allergy testing. A statistically significant difference ECP decrease was observed in our patients.
Discussion: Until now most of the studies previously published in reference to the use of ECP as a biomarker for
monitoring patients on treatment with diets show consistent but insignificant decreases in ECP levels. However, ECP
seems to be a good marker of inflammation if the determinations are performed avoiding confounding factors.
Conclusion: The serial determination of ECP is useful when monitoring patients with EoE treated with specific diets.
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Background
Eosinophilic esophagitis (EoE) can be caused by immuno-
globulin E (IgE)-mediated, non-IgE-mediated or mixed food
sensitization mechanisms. EoE is characterized by the pres-
ence of eosinophil infiltration in the oesophagus, with periph-
eral eosinophilia observed in ~50% of cases. EoE has no
pathognomonic clinical manifestations, is more common in
men, and can manifest at any age [1]. In children, the most
frequent manifestations are feeding difficulties, growth
disorders, vomiting and abdominal pain. In adults, the most
frequent manifestations are dysphagia, gastroesophageal reflux,
abdominal pain and impaction episodes of the alimentary
bolus. Furthermore, an important issue is the lack of correl-
ation between symptom intensity and tissue inflammation.
In patients with dysphagia, endoscopy and anatomo-
pathology testing can confirm cases of EoE in 15 to 35% of
cases [2]. However, reliable inflammatory biomarkers need
to be identified to limit the number of invasive endoscopies
needed for the adequate monitoring of EoE patients.
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It is now acknowledged that EoE requires interdisciplinary
management by gastroenterologists, allergists and anatom-
ical-pathologists. Objective sensitization to food allergens is
fundamental to establishing diets that avoid the evolution of
oesophagitis to fibrosis and the development of oesophageal
stricture states that can trigger serious complications,
including impaction and possibly oesophageal perforation.
Eosinophilic cationic protein (ECP) is a highly cationic
protein with numerous biological functions and cytotoxic
effects, and it is stored by eosinophils and accumulated by
neutrophils. ECP levels can be measured in many biological
fluids, and though it is most commonly used to study
asthma [3], ECP may also be a useful marker for monitor-
ing EoE. In particular, better testing methods are needed in
the context of food avoidance diets, which are often com-
plex and involve multiple testing steps after the sequential
reintroduction of each type of food. Previous studies have
described short patient series in which ECP appears to be a
useful biomarker (determined in blood or faeces). However,
further studies are needed involving larger sample sizes to
determine the usefulness of ECP as a biomarker, not only
for initial avoidance but also for the reintroduction of each
kind of food and subsequent monitoring of EoE patients.
The aim of this study was to better characterize a
number of previously identified biomarkers, including
IgE [4] and ECP [5] levels. We seek to establish the
usefulness of ECP for the monitoring of patients with
EoE under treatment with specific exclusion diets. Con-
sidering that ECP levels can vary due to many factors,
particularly those associated with respiratory pathologies
or poorly controlled diets, one of our priorities was to
eliminate these confounding factors prior to characteriz-
ing this biomarker as a patient monitoring tool.
Methods
Study design
To determine the usefulness of ECP as a biomarker, the
following hypothesis was suggested based on our clinical
experience: Serum ECP levels will significantly decrease
after recommended specific diets have been established fol-
lowing objective food sensitization by means of skin tests
or specific IgE. Furthermore, we expect the objective de-
crease to correlate with clinical improvements and possibly
with the cessation of symptomatic treatments with proton-
pump inhibitors or swallowed/inhaled corticosteroids.
The study included adult and adolescent patients referred
by a digestive medicine specialist with an objective diagno-
sis of EoE, which was based on currently accepted metrics
(15 or more eosinophils per oesophageal mucosal biopsy
field) [1]. A total of 19 subjects were included between 1
January 2012 and 30 June 2015. During the initial appoint-
ment, relevant medical history information was gathered,
and skin tests were performed with complete batteries of
standard aeroallergens (23 items) and food allergens (62
items) (prick tests were performed using standardized aller-
gen extracts from Bial Aristegui® Laboratories). Patients
were then referred to a hospital laboratory for a blood sam-
ple to be taken to establish IgE levels specific to food, blood
count and serum ECP (baseline prior to establishing rele-
vant specific diets). Patients were informed that the blood
sample had to be taken when the subject had no respiratory
symptoms compatible with rhinitis or asthma and no active
infection; the blood sample collection took place outside
the relevant aggravation period in each case (in relation to
aero-allergen sensitization). Appointments were arranged
for all patients to discuss the results of their tests and to
recommend specific diets. We indicated to our patients the
avoidance of food whose sensitization had been objectified
by skin tests, specific IgE levels higher than 0.35 kUA/L as
well as foods with cross-reactivity with pollen to which the
patients were sensitized (mainly fruits and the solanaceae
family). After the diets had been established, appointments
were arranged for the patients between 4 and 6 months
later to assess the clinical response to the specific diets and
to request a second blood sample for blood counts and
serum ECP levels to compare with the previous baseline.
The characteristics of patients included in the study with
analytical values and endoscopic findings are summarized
in Table 1.
Table 1 Characteristics of patients included in the study with
analytical values and endoscopic findings
Number of patients 19
Men/Women 12/7 (63.15%/36.85%)
Age 33.52 ± 13.67
Asthma 4 (21%)
Rhinoconjunctivitis 12 (63.15%)
Atopic dermatitis 5 (26.3%)
Aeroallergens 13 (68.4%)
Food allergies 16 (84.2%)
Overall clinical response to diet
Improvement 15 (79%)
No response 1 (5.22%)
Not included 3 (15.78%)
Endoscopic findings
Eosinophil in biopsies (n/hpf) 22,06 ± 5,34
Inflammatory phenotype 9 (47.36%)
Stenosing phenotipe 4 (21%)
Mixed phenotype 6 (31,64%)
Analytical values
Total IgE 255,53 ± 272,26
ECP Pre diet (μg/mL) 34,25 ± 26,37
Eosinophils in peripheral blood 343,33 ± 177,83
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Patients who did not follow the criteria of providing blood
samples during a period without respiratory symptoms or
outside the aggravation period (the majority of samples were
taken in August, December and January) were excluded.
Furthermore, patients who had previously started diets prior
to consultation were not included in the study.
Patients were told to continue with their symptomatic
treatments as directed by their gastroenterologists for 2 to
3 months and then to stop the treatment and continue
with the diets alone if they began to see improvements.
Histological and endoscopic studies
Endoscopic procedures were performed by an experienced
gastroenterologist using a flexible 8.5 mm gastroscope with
a 2.8 mm work channel (EG-530 FP, Fujinon, Fujifilm
Corporation. Tokyo, Japan). Biopsies were performed using
conventional forceps (Radial JawTM 4 Boston Scientific,
Proparck, Costa Rica). No complications were observed as
a result of the endoscopic procedures or biopsies per-
formed. The histological study was performed only to have
a confirmed diagnosis of EoE, not carrying out a control
study after the maintenance of the indicated diets.
Biopsy specimens were sent to the Pathology Depart-
ment, where they were formalin-fixed and paraffin-
embedded. Serial sections were then performed using a
microtome and stained with eosin haematoxylin. EoE
was diagnosed in cases with 15 eosinophils/hpf or more
in at least one high-power field (HPF).
Analysis
Comparisons were performed using non-parametric
tests of paired samples. Each individual was compared
to their baseline measurements. Continuous variables
(ECP) are expressed in mean ± SD values, and the Wil-
coxon rank test was used to contrast hypotheses regard-
ing continuous variables for pre- and post-diet. Graphs
show box plots with median and interquartile ranges.
Results
Epidemiological data
Nineteen patients diagnosed with EoE (12 males and 7
females) between January 2012 and June 2015, aged be-
tween 17 and 68 (33.52; SD 13.67 years), were included
consecutively. The epidemiological variables are summa-
rized in Table 1.
Clinical data
Most of our patients presented food sensitization, and we
observed atypical food allergies, being the most prevalent
allergy to nuts, legumes, gluten and milk. Objectified food
sensitizations are summarized in Table 2. The most com-
mon atopic feature was rhino-conjunctivitis with some
cases of asthma and atopic dermatitis. The phenotypic di-
versity of the patients studied, from patients with multiple
food and environmental sensitizations to patients with no
atopic trait or associated respiratory pathology, was note-
worthy. We also encountered a number of cases in which
patients said their digestive symptoms were worse during
aggravation periods of their respiratory symptoms due to
pollen exposure.
Analytical values
At baseline, all our patients presented with high ECP
levels compared with the normally accepted standard [6],
with average levels of 34.253 μg/mL ± 26.3725. We first
analysed changes in ECP levels for the 19 cases initially
included in the study without correction for possible diet
transgressions or blood samples taken in a seasonal
period, and we observed a non-statistically significant
reduction in ECP levels to 23.663 (μg/mL) ± 14.692 (p =
0.052). However, when we included only the 16 patients
who followed the protocols regarding dietary transgres-
sions and blood sampling without respiratory symptoms,
we observed a pre-diet ECP mean of 37.3875 ± 26.66871
and post-diet ECP mean of 21.4688 ± 10.56325, which are
significantly different (p < 0.001) (Fig. 1).
Clinical response
Fifteen of the 19 patients showed optimal responses to
their specific diets and remained asymptomatic without
pharmacological treatment. This response was assessed
using the EoO-QOL-A (Adult eosinophilic oesophagitis
quality of life questionnaire) [7]. Of the 4 remaining pa-
tients, empirical diets of 6 food items [8] were indicated
in 2 patients, as sensitization was not established or they
did not respond to specific diets; one of these patients
did not respond to the diet, and the other could not
maintain it. In both cases, these patients continued treat-
ment with inhaled corticosteroids and proton-pump in-
hibitor (PPIs). The remaining two patients continued
with PPIs alone. Two respondent patients required
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symptomatic treatment during the seasonal period and
followed the specific diet for the rest of the year. One of
the patients responding to the specific diet presented
resolution of the mucosal banding observed in the first
endoscopic study. Our intention is to repeat the endo-
scopic study with the remainder of the included
patients.
Discussion
This study shows that ECP may be a useful biomarker for
monitoring EoE patients being treated with specific diets.
We are aware that the small sample size does not allow us
to extrapolate beyond the efficiency of the diets used.
Until now most of the studies previously published in
reference to the use of ECP as a biomarker for monitoring
patients on treatment with diets show consistent but in-
significant decreases in ECP levels following diets. How-
ever, we should highlight other publications in which ECP
and other markers have shown significant decreases in re-
sponse to pharmacological treatment with corticosteroids
or PPIs [9–11]. As discussed in these publications it is im-
perative to achieve an adequate control of our patients
through the use of non-invasive techniques that can be
used in normal clinical practice. In this sense the ECP
seems to be a good marker of inflammation if the determi-
nations are performed correctly.
EoE is a complex entity characterized by a variety of
phenotypes. It predominantly affects men between 30
and 40 years old, and it is generally diagnosed at least
three years after the start of symptoms involving
sensitization to food and environmental aeroallergens
[12]. However, it is becoming increasingly apparent that
EoE may be an under-diagnosed entity with a late diag-
nosis. This delay highlights the importance of actively
searching for patients with compatible symptoms, as
early diagnosis is fundamental to avoiding the develop-
ment of complications, such as impaction of the alimen-
tary bolus. In our experience, doctors should suspect
this condition if patients report episodes of choking or if
one detects “atypical” adult food sensitizations such as
milk, egg and gluten. The patient should then be re-
ferred to a digestive medicine specialist for endoscopy
and biopsy to confirm the suspected diagnosis.
Recent studies [13] have further described the thera-
peutic management of patients with EoE. It is note-
worthy that clinical and histological improvements can
be achieved in 50.5 and 60.8% of patients, respectively,
using PPIs alone. Treatment with topical steroids
(particularly fluticasone and budesonide) is also efficient.
Dietary treatment leads to improvement in patients, with
6-food empirical and elemental diets being more effi-
cient than diets developed based on allergy test results.
The efficiency of the latter diet type is quite variable
according to the literature (from 30 to 70%) [14].
Therefore, there are a number of management and
monitoring solutions available for EoE patients, which
makes selecting the best option for each patient very im-
portant [15].
Although treatment with PPIs or topical corticoste-
roids allows for good control of patients, life-long de-
pendency on this type of treatment is not desirable.
Establishing a diet that allows patients to control their
Fig. 1 Significant differences between baseline ECP levels (34.25 (μg/mL) ± 26.37) and ECP levels after diets (21.46 ± 10.56)
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condition in the long term without depending on
chronic treatment is preferable. As previously discussed,
the phenotypic variability of EoE makes it impossible to
formulate simple treatment rules. A profile must be
established for each patient with esophagitis, and the
treatments must be adapted in each case. Based on our
experience, specific diets were most widely accepted by
patients, as they are easier to follow than the elemental
(unfeasible in adults) and 6-food empirical diets. Unfor-
tunately, this approach is not always possible. In cases in
which we were able to establish diets with clinical re-
sponses and a decrease in ECP levels, we are sequentially
reintroducing the foods in question (initially gluten or
cooked legumes). We observed responses in each case
and assessed the possibility of repeating the endoscopic
study after a certain period of time to assess the re-
sponse and concordance between histology, clinical im-
provement and ECP reduction.
Conclusions
We believe that the serial determination of ECP levels is
useful for monitoring most patients with EoE, given one
avoids confounding factors such as infections, acute
atopic dermatitis, dietary transgressions or respiratory
symptoms, although we are aware that perennial symp-
toms may hinder the utility of this biomarker in many
cases. More studies and batteries with more patients are
needed to better understand this pathology.
Study limitations
Our study has two important limitations: the small num-
ber of patients and the absence of a histological study
after the establishment of the diets and ECP measure-
ment. We are currently including more patients, al-
though this is complicated by the low prevalence of this
disease. Although an anatomo-pathological study is de-
sirable as a gold standard, it is ethically questionable to
subject an asymptomatic patient to an invasive tech-
nique with potential complications. We must remember
that most of our patients remain asymptomatic without
pharmacological treatment.
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